Kizilcan Cetin, S. Et Al. 2023. Familial Clinical Heterogeneity of Medullary Thyroid Cancer with Germline RET S891A Protooncogene Mutation: 7-Year Follow-up with Successful Sorafenib Treatment.. Journal of clinical research in pediatric endocrinology .

Kizilcan Cetin, S., Siklar, Z., Ozsu, E., Ceran, A., Ceyhan, K., Aycan, Z., ... Kırmızı, A.(2023). Familial Clinical Heterogeneity of Medullary Thyroid Cancer with Germline RET S891A Protooncogene Mutation: 7-Year Follow-up with Successful Sorafenib Treatment.. Journal of clinical research in pediatric endocrinology .

Kizilcan Cetin, Sirmen Et Al. "Familial Clinical Heterogeneity of Medullary Thyroid Cancer with Germline RET S891A Protooncogene Mutation: 7-Year Follow-up with Successful Sorafenib Treatment.," Journal of clinical research in pediatric endocrinology , 2023

Kizilcan Cetin, Sirmen K. Et Al. "Familial Clinical Heterogeneity of Medullary Thyroid Cancer with Germline RET S891A Protooncogene Mutation: 7-Year Follow-up with Successful Sorafenib Treatment.." Journal of clinical research in pediatric endocrinology , 2023

Kizilcan Cetin, S. Et Al. (2023) . "Familial Clinical Heterogeneity of Medullary Thyroid Cancer with Germline RET S891A Protooncogene Mutation: 7-Year Follow-up with Successful Sorafenib Treatment.." Journal of clinical research in pediatric endocrinology .

@article{article, author={Sirmen Kizilcan Cetin Et Al. }, title={Familial Clinical Heterogeneity of Medullary Thyroid Cancer with Germline RET S891A Protooncogene Mutation: 7-Year Follow-up with Successful Sorafenib Treatment.}, journal={Journal of clinical research in pediatric endocrinology}, year=2023}